stockgist
HomeTop MoversCompaniesConcepts

Market

  • Top Movers
  • Companies
  • Concepts

SEC Filings

  • AI Filing Analysis
  • Financial Reports
  • Current Reports
  • IPO Filings

Ownership

  • Institutional Holdings
  • Insider Trading

About

  • Data updates every 5 min
  • SEC EDGAR Source
© 2025–2026 StockGist|Information only, not investment advice
    1. Companies
    2. AIMD
    stockgist
    HomeTop MoversCompaniesConcepts
    AIMD logo

    Ainos, Inc.

    AIMD
    NASDAQ
    Healthcare
    Biotechnology
    San Diego, CA, US44 employeesainos.com
    $1.44
    +0.00(0.00%)

    Mkt Cap $6M

    $1.29
    $4.25

    52-Week Range

    At a Glance

    AI-generated

    Revenue surged 499% to $124.2K with gross profit turning positive at $102.9K (82.9% margin), but operating loss widened slightly to $14.0M and net loss to $14.8M amid heavy R&D investment.

    8-K
    Ainos, Inc. reported a 499% revenue increase for FY2025 with gross margin turning positive to 82.9%, alongside a net loss of $14.8 million and subsequent new financing.

    $6M

    Market Cap

    $119.7K

    Revenue

    -$16M

    Net Income

    Employees44
    Fundamentals

    How The Business Makes Money

    Ainos, Inc., a healthcare company, engages in the developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. The company was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. Ainos, Inc. was incorporated in 1984 and is based in San Diego, California.

    Industry Biotechnology
    Activity

    What Changed Recently

    Financial Results
    Mar 29, 2026

    (including Exhibit 99.1) shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”

    Other Event
    Jan 5, 2026

    Other Events. On December 30, 2025, Ainos, Inc. (the “Company”), a Texas corporation, entered into a distribution agreement (the “Distribution Agreement”) with

    Regulation FD
    Jan 4, 2026

    of this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”

    Peer Companies

    CompanyPriceChangeMarket CapP/E
    ANLAdlai Nortye Ltd.$8.65+9.56%$270M-1.4
    THARTharimmune, Inc.$3.29+6.82%$130M-2.0
    ATHAATHA$6.75-6.12%$27M—
    DAREDaré Bioscience, Inc.$1.75-8.11%$17M-1.0
    ICUSeaStar Medical Holding C...$4.46+25.42%$12M-0.4
    BLRXBioLineRx Ltd.$2.21+1.50%$10M-3.3
    FBLGFibroBiologics, Inc. Comm...$1.37+2.99%$3M-0.6
    MBRXMoleculin Biotech, Inc.$2.32+4.04%$3M-1.0
    Analyst View
    Company Profile
    CIK0001014763
    ISINUS00902F4028
    CUSIP00902F402
    Phone858 869 2986
    Address8880 Rio San Diego Drive, San Diego, CA, 92108, US
    SEC EDGAR

    Market

    • Top Movers
    • Companies
    • Concepts

    SEC Filings

    • AI Filing Analysis
    • Financial Reports
    • Current Reports
    • IPO Filings

    Ownership

    • Institutional Holdings
    • Insider Trading

    About

    • Data updates every 5 min
    • SEC EDGAR Source
    © 2025–2026 StockGist|Information only, not investment advice